Harvard Bioscience Revenue Rises 8% in Third Quarter
The Holliston, Massachusetts life sciences tools maker reported higher sales but a wider net loss for the quarter ended September 30, 2026.
Updated on Nov. 10, 2026 in Healthcare

Harvard Bioscience reported third quarter 2026 revenue of $22.2 million, up from $20.6 million a year earlier, and reaffirmed its full-year 2026 revenue growth guidance of 3% to 5%. The company posted a net loss of $2.6 million for the quarter, compared with a net loss of $1.2 million in the third quarter of 2025.
Why it matters
Growth was driven by double-digit revenue gains from contract research organizations and customers in China, while gross margin narrowed to 55.4% from 58.4%. The results show revenue momentum for the Massachusetts-based company alongside continued pressure on profitability.
Third quarter 2026 adjusted EBITDA was $1.8 million, down from $2.0 million a year earlier, and cash used in operations was $0.2 million. Nine-month net loss narrowed to $9.0 million from $53.9 million, a comparison that reflects a $48.0 million goodwill impairment recorded in the first quarter of 2025.
The players
Harvard Bioscience
Harvard Bioscience is a Holliston, Massachusetts-based developer and seller of life science research tools and equipment used by academic and pharmaceutical laboratories.
The details
Revenue growth was driven by sales of products for organoids, respiratory, and fluidics, and by revamped sales and marketing teams. The full-year adjusted EBITDA target was updated to account for higher-than-expected sales of certain lower-margin CMT products and greater revenue contribution from distribution channels and China. The company also effected a 1-for-10 reverse stock split on March 13, 2026.
Timeline
March 13, 2026: A 1-for-10 reverse stock split took effect.
September 30, 2026: The third quarter 2026 period ended.
November 10, 2026: Third quarter results were announced and a conference call was held.
End of first quarter 2027: Project Viking is expected to be completed.
Roadmap
The quarter follows the company's 2025 goodwill impairment of $48.0 million and its March 2026 reverse stock split, which were part of its effort to reset the business. Revenue growth has returned, but the narrowing of nine-month losses from $53.9 million to $9.0 million largely reflects the absence of that impairment rather than operating improvement.
Revenue growth from research customers suggests continued demand for the company's lab tools, which can affect pricing and availability for the institutions that buy them. Investors and customers should watch whether margin pressure from lower-margin product mix and distribution channels persists.
The takeaway
Harvard Bioscience returned to revenue growth in the third quarter, but a narrower gross margin and continued net losses show that top-line gains have not yet translated into stronger profitability. Readers tracking the company should compare the fourth quarter results against the guided revenue range.
What happens next
The company expects fourth quarter 2026 revenue between $23.7 million and $25.5 million, and Project Viking is expected to be completed by the end of the first quarter of 2027.
Further reading
For more on the state's medical and life sciences industry, explore Healthcare coverage.
Source note: This article includes information reported by The Manila times.






